Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Finds IMS Data Solution, Uncovers Gemzar Dilution In Kansas City

Executive Summary

Lilly's decision to use IMS Health's wholesale tracking data in the Kansas City area for oncology sales rep bonuses helped lead to the discovery that an area pharmacist appeared to be diluting chemotherapy drugs.

You may also be interested in...



FDA Oversight Of Rx Compounding Should Increase, GAO Study Suggests

Increased FDA oversight of pharmacy compounding may be necessary due to state budgetary constraints, an Oct. 23 General Accounting Office report suggests

FDA Oversight Of Rx Compounding Should Increase, GAO Study Suggests

Increased FDA oversight of pharmacy compounding may be necessary due to state budgetary constraints, an Oct. 23 General Accounting Office report suggests

Lilly, Bristol Drug Dilution Settlement May Increase Focus On “Gray Market”

The size of settlement payments made by Lilly and Bristol-Myers Squibb in the Kansas City drug dilution case is the latest warning to manufacturers that they may need to become more aggressive in policing the so-called "gray market" for pharmaceuticals

Related Content

UsernamePublicRestriction

Register

PS038442

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel